LDS/Medical Tests/Peutz-Jeghers Syndrome (STK11) Gene Mutation Analysis

Peutz-Jeghers Syndrome (STK11) Gene Mutation Analysis

Peutz-Jeghers syndrome (PJS) is an autosomal dominant syndrome characterized by mucocutaneous hyperpigmentation of the lips, buccal mucosa, and digits, gastrointestinal hamartomatous polyposis, and an increased risk for the development of various neoplasms. Peutz-Jeghers-type hamartomatous polyps are most common in the small intestine but can also occur in the stomach, large bowel, and extraintestinal sites including the renal pelvis, bronchus, gall bladder, nasal passages, urinary bladder, and ureters. Gastrointestinal polyps can result in chronic bleeding and anemia and cause recurrent obstruction or intussusception requiring surgical resection. Individuals with PJS are also at increased risk for a wide variety of epithelial malignancies (colorectal, gastric, pancreatic, breast, and ovarian cancers).

Mutations in the serine-threonine kinase 11 (STK11/LKB1) gene on chromosome 19p13.3 causes PJS although mutations in other genes (SMAD4, BMPRIA, PTEN, PRKARIA, APC, MLH1, MSH2, MSH3, MSH6, PMS1 and PMS2) cause syndromes which overlap with PJS. Mutation in STK11 alters the structure or function of the STK11 protein, disrupting its ability to restrain cell division. The resulting uncontrolled cell growth leads to the formation of hamartomatous polyps and predispose to cancer development in affected individuals. Germline mutations of STK11 are documented in up to 70%-80% of patients with PJS and up to 15% of cases have deletions of all or part of STK11. The prevalence of this condition is estimated to be 1 in 25,000 to 300,000 individuals.

  • Diagnostic confirmation of Peutz-Jeghers syndrome
  • Carrier screening in family members of the affected patient
  • Prenatal diagnosis in at-risk pregnancies
  • Help to guide treatment and management decisions
Any heterozygous mutation or pathogenic variant in STK11 gene is consistent with Peutz-Jeghers syndrome. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

No pathogenic variants (mutations) detected

Bidirectional sequence analysis for the presence of a mutation in exons 1 through 9 of the STK11 gene.

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
STK11 deletion/duplication analysis, Hereditary Cancers Panel.

3-7 days.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login